# Clinical and Molecular Characteristics of Foveal Sparing Phenotype in Chinese Patients With Inherited Retinal Diseases

**Authors:** Zilin Wang, Tong Li, Jieqiong Chen, Yiqing Sun, Huixun Jia, Junran Sun, Xiaodong Sun

PMC · DOI: 10.1167/tvst.15.2.18 · Translational Vision Science & Technology · 2026-02-17

## TL;DR

This study examines the foveal sparing phenotype in Chinese patients with inherited retinal diseases, finding it is linked to better vision and more common in certain genetic types.

## Contribution

The study identifies the foveal sparing phenotype's association with specific IRD genes and introduces residual ellipsoid zone area as a predictive biomarker.

## Key findings

- Foveal sparing is more common in EYS and USH2A-related retinopathy.
- Residual ellipsoid zone area on OCT correlates with visual acuity and predicts vision deterioration.
- The foveal sparing phenotype is linked to better visual prognosis in IRD patients.

## Abstract

The purpose of this study was to evaluate the clinical characteristics of the foveal sparing phenotype among patients with inherited retinal diseases (IRDs) and to identify the predictive imaging markers for visual prognosis.

Consecutive patients with definitive clinical and genetic diagnoses of IRD who first visited our clinic from November 2021 to December 2022 and had high-quality spectral-domain optical coherence tomography (SD-OCT) images were included in this retrospective cohort. The foveal sparing phenotype was defined by foveal preservation on autofluorescence (FAF) and OCT images. Best-corrected visual acuity (BCVA) and dimensions of residual structures of outer retinal layers on OCT and FAF images were measured and analyzed. Spearman correlation analysis was performed to evaluate the correlation between retinal imaging features and BCVA. Receiver operating characteristic (ROC) curve was performed to assess the predictive performance of residual ellipsoid zone (EZ) area on OCT.

A total of 601 eyes of 308 Chinese patients with IRD were enrolled. Foveal sparing phenotype was observed in 195 (32.4%) eyes of 105 (34.1%) patients. There were 46.7% of cases with USH2A-related retinopathy and 76.9% EYS-related retinopathy presented foveal sparing phenotype, whereas their structural integrity showed no significant difference. Spearman correlation analyses revealed significant association between residual EZ area (P < 0.01) and BCVA. ROC curve analysis demonstrated that the residual EZ area at initial diagnosis could predict the degree of BCVA deterioration within 2 years (area under the curve [AUC] = 0.70).

Our findings indicate that the foveal sparing phenotype is associated with better visual prognosis and is more frequently observed in IRDs associated with EYS and USH2A mutations. The residual EZ area on OCT can serve as a predictor of the timeframe for central vision deterioration to blindness in patients with IRD.

Residual EZ area on OCT can serve as a predictive biomarker to support clinical decision making in monitoring and managing the progression of IRD.

## Linked entities

- **Genes:** USH2A (usherin) [NCBI Gene 7399], EYS (EGF-like photoreceptor maintenance factor) [NCBI Gene 346007]

## Full-text entities

- **Genes:** CEP78 (centrosomal protein 78) [NCBI Gene 84131] {aka C9orf81, CRDHL, IP63}, VAX2 (ventral anterior homeobox 2) [NCBI Gene 25806] {aka DRES93}, TOPORS (TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase) [NCBI Gene 10210] {aka LUN, P53BP3, RP31, TP53BPL}, PCDH15 (protocadherin related 15) [NCBI Gene 65217] {aka CDHR15, DFNB23, USH1F}, RHO (rhodopsin) [NCBI Gene 6010] {aka CSNBAD1, OPN2, RP4}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, ARHGEF18 (Rho/Rac guanine nucleotide exchange factor 18) [NCBI Gene 23370] {aka P114-RhoGEF, RP78, SA-RhoGEF, p114RhoGEF}, NYX (nyctalopin) [NCBI Gene 60506] {aka CLRP, CSNB1, CSNB1A, CSNB4, NBM1}, POC1B (POC1 centriolar protein B) [NCBI Gene 282809] {aka CORD20, PIX1, TUWD12, WDR51B}, USH2A (usherin) [NCBI Gene 7399] {aka RP39, US2, USH2, dJ1111A8.1}, KLHL7 (kelch like family member 7) [NCBI Gene 55975] {aka CISS3, KLHL6, PERCHING, SBBI26}, TRPM1 (transient receptor potential cation channel subfamily M member 1) [NCBI Gene 4308] {aka CSNB1C, LTRPC1, MLSN1}, CNGA3 (cyclic nucleotide gated channel subunit alpha 3) [NCBI Gene 1261] {aka ACHM2, CCNC1, CCNCa, CCNCalpha, CNCG3, CNG3}, TGFBI (transforming growth factor beta induced) [NCBI Gene 7045] {aka BIGH3, CDB1, CDG2, CDGG1, CSD, CSD1}, IMPG1 (interphotoreceptor matrix proteoglycan 1) [NCBI Gene 3617] {aka GP147, IPM150, RP91, SPACR, VMD4}, MERTK (MER proto-oncogene, tyrosine kinase) [NCBI Gene 10461] {aka MER, RP38, Tyro12, c-Eyk, c-mer}, EFEMP1 (EGF-like fibulin extracellular matrix protein 1) [NCBI Gene 2202] {aka ARCL1D, DHRD, DRAD, FBLN3, FBNL, FIBL-3}, RDH5 (retinol dehydrogenase 5) [NCBI Gene 5959] {aka 9cRDH, HSD17B9, RDH1, SDR9C5}, PRPF31 (pre-mRNA processing factor 31) [NCBI Gene 26121] {aka NY-BR-99, PRP31, RP11, SNRNP61}, COL11A1 (collagen type XI alpha 1 chain) [NCBI Gene 1301] {aka CO11A1, COLL6, DFNA37, STL2}, CNGB1 (cyclic nucleotide gated channel subunit beta 1) [NCBI Gene 1258] {aka CNCG2, CNCG3L, CNCG4, CNG4, CNGB1B, GAR1}, FRMD7 (FERM domain containing 7) [NCBI Gene 90167] {aka NYS, NYS1, XIPAN}, GNPTAB (N-acetylglucosamine-1-phosphate transferase subunits alpha and beta) [NCBI Gene 79158] {aka GNPTA, ICD}, IQCB1 (IQ motif containing B1) [NCBI Gene 9657] {aka NPHP5, PIQ, SLSN5}, ACO2 (aconitase 2) [NCBI Gene 50] {aka ACONM, HEL-S-284, ICRD, OCA8, OPA9}, CAPN5 (calpain 5) [NCBI Gene 726] {aka ADNIV, HTRA3, VRNI, nCL-3}, PCARE (photoreceptor cilium actin regulator) [NCBI Gene 388939] {aka C2orf71, RP54}, ADGRV1 (adhesion G protein-coupled receptor V1) [NCBI Gene 84059] {aka FEB4, GPR98, MASS1, USH2B, USH2C, VLGR1}, RGS9BP (regulator of G protein signaling 9 binding protein) [NCBI Gene 388531] {aka R9AP}, REEP6 (receptor accessory protein 6) [NCBI Gene 92840] {aka C19orf32, DP1L1, REEP6.1, REEP6.2, RP77, TB1}, SMARCA4 (SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4) [NCBI Gene 6597] {aka BAF190, BAF190A, BRG1, CSS4, MRD16, OTSC12}, GUCA1A (guanylate cyclase activator 1A) [NCBI Gene 2978] {aka C6orf131, COD3, CORD14, GCAP, GCAP-1, GCAP-I}, BEST1 (bestrophin 1) [NCBI Gene 7439] {aka ARB, BEST, BMD, Best1V1Delta2, RP50, TU15B}, LRP2 (LDL receptor related protein 2) [NCBI Gene 4036] {aka DBS, GP330, LRP-2}, GUCY2D (guanylate cyclase 2D, retinal) [NCBI Gene 3000] {aka CACD, CACD1, CG-E, CORD5, CORD6, CSNB1I}, CLN3 (CLN3 lysosomal/endosomal transmembrane protein, battenin) [NCBI Gene 1201] {aka BTN1, BTS, JNCL, RP101, SLC29B1}, CRB1 (crumbs cell polarity complex component 1) [NCBI Gene 23418] {aka CRB1-A, CRB1-B, CRB1-C, LCA8, RP12}, LRP5 (LDL receptor related protein 5) [NCBI Gene 4041] {aka BMND1, EVR1, EVR4, HBM, LR3, LRP-5}, ABCA4 (ATP binding cassette subfamily A member 4) [NCBI Gene 24] {aka ABC10, ABCR, ARMD2, CORD3, FFM, RMP}, RP1 (RP1 axonemal microtubule associated) [NCBI Gene 6101] {aka DCDC4A, ORP1}, LCA5 (lebercilin LCA5) [NCBI Gene 167691] {aka C6orf152}, CERKL (CERK like autophagy regulator) [NCBI Gene 375298] {aka RP26}, ALMS1 (ALMS1 centrosome and basal body associated protein) [NCBI Gene 7840] {aka ALSS}, FZD4 (frizzled class receptor 4) [NCBI Gene 8322] {aka CD344, EVR1, FEVR, FZD4S, Fz-4, Fz4}, IMPG2 (interphotoreceptor matrix proteoglycan 2) [NCBI Gene 50939] {aka IPM200, RP56, SPACRCAN, VMD5}, EYS (EGF-like photoreceptor maintenance factor) [NCBI Gene 346007] {aka C6orf178, C6orf179, C6orf180, EGFL10, EGFL11, RP25}, BBS2 (Bardet-Biedl syndrome 2) [NCBI Gene 583] {aka BBS, RP74}, PEX1 (peroxisomal biogenesis factor 1) [NCBI Gene 5189] {aka HMLR1, PBD1A, PBD1B, ZWS, ZWS1}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, MAN2B1 (mannosidase alpha class 2B member 1) [NCBI Gene 4125] {aka LAMAN, MANB}, FBN1 (fibrillin 1) [NCBI Gene 2200] {aka ACMICD, ECTOL1, FBN, GPHYSD2, MASS, MFLS}, TSPAN12 (tetraspanin 12) [NCBI Gene 23554] {aka EVR5, NET-2, NET2, TM4SF12}, IDUA (alpha-L-iduronidase) [NCBI Gene 3425] {aka IDA, MPS1, MPSI}, RBP3 (retinol binding protein 3) [NCBI Gene 5949] {aka D10S64, D10S65, D10S66, IRBP, RBPI, RP66}, PDE6A (phosphodiesterase 6A) [NCBI Gene 5145] {aka CGPR-A, PDEA, RP43}, RPE65 (retinoid isomerohydrolase RPE65) [NCBI Gene 6121] {aka BCO3, LCA2, RP20, mRPE65, p63, rd12}, AIPL1 (AIP like 1 HSP90 co-chaperone) [NCBI Gene 23746] {aka AIPL2, LCA4}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, PDE6B (phosphodiesterase 6B) [NCBI Gene 5158] {aka CSNB3, CSNBAD2, GMP-PDEbeta, PDEB, RP40, rd1}, ARR3 (arrestin 3) [NCBI Gene 407] {aka ARRX, MYP26, cArr}
- **Diseases:** retinal atrophy (MESH:D012173), retinal dystrophies (MESH:D058499), toxicity (MESH:D064420), BCVA (MESH:D057826), Leber congenital amaurosis (MESH:D057130), CORD (OMIM:120970), BBS (MESH:D020788), Fovea (MESH:C538369), IRD (MESH:D052919), photoreceptor degeneration (MESH:D009410), ELM (MESH:D015433), IRDs (MESH:D012164), Choroidal atrophy (MESH:C535810), retina degeneration (MESH:D007625), BCD (MESH:C535440), FS (MESH:D052159), cone rod dystrophy (MESH:D000071700), atrophy (MESH:D001284), Choriocapillaris (MESH:D008268), photoreceptor loss (MESH:D016388), LCA (MESH:C536600), trauma (MESH:D014947), central vision deterioration (MESH:D014786), retinal pigment epithelium loss (MESH:C536309), night blindness (MESH:D009755), ischemia (MESH:D007511), hypoxia (MESH:D000860), FAF (MESH:C537858), visual deterioration (MESH:C531604), blindness (MESH:D001766), GA (MESH:D057092), EYS-RP (MESH:D012174), STGD (MESH:D000080362), retinopathy (MESH:D058437)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** c.2299delG, AUC of 0

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12922713/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12922713/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC12922713/full.md

---
Source: https://tomesphere.com/paper/PMC12922713